Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Start-ups
Kymera scores $65 million financing round
by Lisa Jarvis
November 18, 2018
| A version of this story appeared in
Volume 96, Issue 46
Kymera Therapeutics has closed its second sizable financing round, securing $65 million from a syndicate of investors co-led by 6 Dimensions Capital, Bessemer Venture Partners, and Pfizer Ventures. Kymera, which was one of C&EN’s 10 Start-Ups to Watch this year, was founded in 2016 to develop protein degraders, complex small molecules that tag an errant protein for the cellular trash bin. The company, which has now raised nearly $100 million, expects to put its first drug into human tests in 2020.
Chemical & Engineering News
ISSN 0009-2347
Copyright © 2024 American Chemical Society
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X